Biological
RP1
RP1 is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Active, not recruiting3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
active_not_recruiting375%
unknown125%
Recent Activity
3 active trials
Showing 4 of 4
active_not_recruitingphase_2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348
active_not_recruitingphase_1
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
NCT05858229
unknown
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
NCT06590480
active_not_recruitingphase_2
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436
Clinical Trials (4)
Showing 4 of 4 trials
NCT03767348Phase 2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT05858229Phase 1
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
NCT06590480
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
NCT04050436Phase 2
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4